FDA Approves Sarclisa Escena (isatuximab-irfc) Subcutaneous Injection for the Treatment of Multiple Myeloma
RegulatoryapprovedSarclisa EscenaPositive
AI Analysis
Summary
The FDA has approved Sarclisa Escena (isatuximab-irfc) subcutaneous injection in combination with standard-of-care regimens for treating patients with multiple myeloma. This approval represents a new subcutaneous formulation of the monoclonal antibody therapy.
Outcome Details
FDA approval for subcutaneous injection formulation in combination with standard-of-care regimens for multiple myeloma
Importance:8/10
Sentiment:
0.90
FDA approvaloncologymultiple myelomasubcutaneous formulationSarclisa
Related Companies
Read the original article
Published by Drugs.com New Drug Approvals on July 10, 2026 8:07 PM